Feedback / Questions
ADI-001 - Adicet Bio
https://www.businesswire.com/news/home/20230626163061/en/Adicet-Bio-Reports-Positive-Data-from-Ongoing-ADI-001-Phase-1-Trial-in-Patients-with-Relapsed-or-Refractory-Aggressive-B-Cell-Non-Hodgkin%E2%80%99s-Lymphoma-NHL
Jun 26, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next